Sanofi of­floads French rights for an­tipsy­chot­ic to neigh­bor­ing phar­ma

Sanofi has hand­ed off the French rights to an­ti-psych drug Ter­alithe to a small French phar­ma — both a di­vis­i­ble tablet and a pro­longed-re­lease tablet of lithi­um car­bon­ate.

The French com­pa­ny Lab­o­ra­toires Del­bert made the an­nounce­ment ear­ly Mon­day, and while it didn’t dis­close the fi­nan­cials, the com­pa­ny said it was able to fund the ac­qui­si­tion thanks to a strong re­la­tion­ship with un­named part­ners who “strong­ly be­lieve in their val­ues fo­cused on pa­tients’ ac­cess to MITM (Ma­jor Ther­a­peu­ti­cal In­ter­est Med­ica­tions).”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER